The authors also proposed that the expression of ER and phosphorylated STAT3 (pSTAT3) may be considered independent prognostic factors in breast cancer, and that targeting IL-6/STAT3 could have clinical potential in ER-positive, endocrine therapy-refractory patients [87]. This evidence concerns the gene IL6 and breast carcinoma.